External Beam Radiation in Differentiated Thyroid Carcinoma

The treatment of differentiated thyroid carcinoma (DTC) is surgery followed in some cases by adjuvant treatment, mostly with radioactive iodine (RAI). External beam radiotherapy (EBRT) is less common and not a well-established treatment modality in DTC. The risk of recurrence depends on three major...

Full description

Bibliographic Details
Main Authors: Salem Billan, Tomer Charas
Format: Article
Language:English
Published: Rambam Health Care Campus 2016-01-01
Series:Rambam Maimonides Medical Journal
Subjects:
Online Access:http://rmmj.org.il/Pages/ArticleHTM.aspx?manuId=562
id doaj-09650322b9d24d76974dcc20d372dfc6
record_format Article
spelling doaj-09650322b9d24d76974dcc20d372dfc62020-11-24T23:32:53ZengRambam Health Care CampusRambam Maimonides Medical Journal2076-91722016-01-0171e000810.5041/RMMJ.10235External Beam Radiation in Differentiated Thyroid CarcinomaSalem Billan0Tomer Charas1Department of Oncology, Princess Margaret Hospital, Toronto, CanadaDivision of Oncology, Rambam Health Care Campus, Haifa, IsraelThe treatment of differentiated thyroid carcinoma (DTC) is surgery followed in some cases by adjuvant treatment, mostly with radioactive iodine (RAI). External beam radiotherapy (EBRT) is less common and not a well-established treatment modality in DTC. The risk of recurrence depends on three major prognostic factors: extra-thyroid extension, patient’s age, and tumor with reduced iodine uptake. Increased risk for recurrence is a major factor in the decision whether to treat the patient with EBRT. Data about the use of EBRT in DTC are limited to small retrospective studies. Most series have demonstrated an increase in loco-regional control. The risk/benefit from giving EBRT requires careful patient selection. Different scoring systems have been proposed by different investigators and centers. The authors encourage clinicians treating DTC to become familiarized with those scoring systems and to use them in the management of different cases. The irradiated volume should include areas of risk for microscopic disease. Determining those areas in each case can be difficult and requires detailed knowledge of the surgery and pathological results, and also understanding of the disease-spreading pattern. Treatment with EBRT in DTC can be beneficial, and data support the use of EBRT in high-risk patients. Randomized controlled trials are needed for better confirmation of the role of EBRT.http://rmmj.org.il/Pages/ArticleHTM.aspx?manuId=562Carcinomaexternal beamradiotherapythyroid
collection DOAJ
language English
format Article
sources DOAJ
author Salem Billan
Tomer Charas
spellingShingle Salem Billan
Tomer Charas
External Beam Radiation in Differentiated Thyroid Carcinoma
Rambam Maimonides Medical Journal
Carcinoma
external beam
radiotherapy
thyroid
author_facet Salem Billan
Tomer Charas
author_sort Salem Billan
title External Beam Radiation in Differentiated Thyroid Carcinoma
title_short External Beam Radiation in Differentiated Thyroid Carcinoma
title_full External Beam Radiation in Differentiated Thyroid Carcinoma
title_fullStr External Beam Radiation in Differentiated Thyroid Carcinoma
title_full_unstemmed External Beam Radiation in Differentiated Thyroid Carcinoma
title_sort external beam radiation in differentiated thyroid carcinoma
publisher Rambam Health Care Campus
series Rambam Maimonides Medical Journal
issn 2076-9172
publishDate 2016-01-01
description The treatment of differentiated thyroid carcinoma (DTC) is surgery followed in some cases by adjuvant treatment, mostly with radioactive iodine (RAI). External beam radiotherapy (EBRT) is less common and not a well-established treatment modality in DTC. The risk of recurrence depends on three major prognostic factors: extra-thyroid extension, patient’s age, and tumor with reduced iodine uptake. Increased risk for recurrence is a major factor in the decision whether to treat the patient with EBRT. Data about the use of EBRT in DTC are limited to small retrospective studies. Most series have demonstrated an increase in loco-regional control. The risk/benefit from giving EBRT requires careful patient selection. Different scoring systems have been proposed by different investigators and centers. The authors encourage clinicians treating DTC to become familiarized with those scoring systems and to use them in the management of different cases. The irradiated volume should include areas of risk for microscopic disease. Determining those areas in each case can be difficult and requires detailed knowledge of the surgery and pathological results, and also understanding of the disease-spreading pattern. Treatment with EBRT in DTC can be beneficial, and data support the use of EBRT in high-risk patients. Randomized controlled trials are needed for better confirmation of the role of EBRT.
topic Carcinoma
external beam
radiotherapy
thyroid
url http://rmmj.org.il/Pages/ArticleHTM.aspx?manuId=562
work_keys_str_mv AT salembillan externalbeamradiationindifferentiatedthyroidcarcinoma
AT tomercharas externalbeamradiationindifferentiatedthyroidcarcinoma
_version_ 1725532898932555776